Current and Emerging Therapies for Systemic Mastocytosis

[1] Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature [J]. ONCOTARGET, 2017, 8 (40) : 68950 - 68963

[2] Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis [J]. BLOOD, 2015, 126 (08) : 1009 - 1016

[3] Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (04) : 1097 - 1106

[4] Epidemiology of systemic mastocytosis in Denmark [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (04) : 521 - 528

[5] Dave N, 2021, CANCER RES, V81

[6] Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM) [J]. BLOOD, 2022, 140 : 1512 - 1513

[7] Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial [J]. NATURE MEDICINE, 2021, 27 (12) : 2183 - +

[8] The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis [J]. ANNALS OF HEMATOLOGY, 2014, 93 (01) : 81 - 88

[9] A precision therapy against cancers driven by KIT/PDGFRA mutations [J]. SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (414)

[10] Gotlib Jason, 2023, NEJM Evid, V2, pEVIDoa2200339, DOI 10.1056/EVIDoa2200339

[1] Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature [J]. ONCOTARGET, 2017, 8 (40) : 68950 - 68963

[2] Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis [J]. BLOOD, 2015, 126 (08) : 1009 - 1016

[3] Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (04) : 1097 - 1106

[4] Epidemiology of systemic mastocytosis in Denmark [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (04) : 521 - 528

[5] Dave N, 2021, CANCER RES, V81

[6] Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM) [J]. BLOOD, 2022, 140 : 1512 - 1513

[7] Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial [J]. NATURE MEDICINE, 2021, 27 (12) : 2183 - +

[8] The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis [J]. ANNALS OF HEMATOLOGY, 2014, 93 (01) : 81 - 88

[9] A precision therapy against cancers driven by KIT/PDGFRA mutations [J]. SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (414)

[10] Gotlib Jason, 2023, NEJM Evid, V2, pEVIDoa2200339, DOI 10.1056/EVIDoa2200339